Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Stewart Compounding Pharmacy
WARNING LETTER
•Stewart Compounding Pharmacy•March 25, 2013

Stewart Compounding Pharmacy – FDA Warning Letter, Mar 25, 2013

Record Details

From March 18 to March 25, 2013, an FDA inspection of Stewart Pharmaceuticals, Inc. (dba Stewart Compounding Pharmacy) identified serious violations. The firm was producing a significant number of drug products without valid prescriptions for individually-identified patients, which means these drugs do not qualify for exemptions under section 503A of the FDCA or FDA's enforcement discretion per CPG 460.200. This renders them misbranded under section 502(f)(1) of the FDCA because they lack adequate directions for use.

Furthermore, the inspection revealed serious deficiencies in sterile drug product production, leading to adulteration under section 501(a)(2)(A) and 501(a)(2)(B) of the FDCA. Violations included performing processing and filling of syringes in an unclassified area without further sterilization, lack of smoke studies, unsuitable and improperly tested sterilization equipment, and personnel not using sterile garments. Since the firm manufactures and distributes drugs without valid prescriptions, its operations are subject to CGMP regulations (21 CFR Parts 210 and 211). Specific CGMP violations included failure to establish and follow procedures for preventing microbiological contamination (21 CFR 211.113(b)), inadequate personnel clothing (21 CFR 211.28(a)), insufficient environmental monitoring (21 CFR 211.

Company
Stewart Compounding Pharmacy
Inspection date
March 25, 2013
Product type
Drugs
Office
Atlanta District Office
People
  • John R. Gridley
  • Marie Mathews
View Company Profile

ID · 485d2d79-13ef-4311-8498-73d7dfb8be33

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21 U.S.C. 351(a)(2)(A)21 U.S.C. 331(k)21 CFR 211.113(b)21 CFR 211.28(a)21 CFR 211.42(c)(10)(iv)21 CFR 211.167(a)21 CFR 211.166(a)

Full citation text and observation details available on the Dashboard.

Other documents for Stewart Compounding Pharmacy
  • 483 - 2014-10-10October 10, 2014
  • 483 - 2014-02-26February 26, 2014
  • 483 - 2013-03-25March 25, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Stewart Compounding Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.